

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 10-817-US)**

In re Application of:)	
)	
J. Crowley, et al.)	
)	Group Art Unit: 1651
Serial No.: 10/591,118)	
)	Examiner: Barnhart, L.E.
Filed: September 28, 2007)	
)	Confirm. No.: 7739
For: Process for Cell Culturing by Continuous) Perfusion and Alternating Tangential Flow)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. A Copy of the foreign reference is enclosed herewith. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

This Information Disclosure Statement is being filed:

**McDonnell, Boehnen, Hulbert & Berghoff LLP
300 S. Wacker Drive, Suite 3100
Chicago, IL 60606
312-913-0001**

☐ within three months of the filing date of a national application; within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or before the mailing date of a first Office Action on the merits. 37 C.F.R. §1.97 (b)

☐ **after** three months of the filing date of a national application, or the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or **after** the mailing date of a first Office Action on the merits, but **before** the mailing date of a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), and includes (37 C.F.R. § 1.97 (c):

☐ the Certification under 37 C.F.R. § 1.97(e) (see “Certification” below)

OR

☒ the fee of \$180 set forth in 37 C.F.R. § 1.17(p) (see “Fees” below).

☐ **after** a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), but before, or simultaneously with, the payment of the issue fee, and includes the Certification under 37 C.F.R. § 1.97(e) (see “Certification” below), and the Petition Fee set forth in 37 C.F.R. § 1.17(i) (see “Fees” and “Method of Payment of Fees” below). Applicants hereby petitions for consideration of the Information Disclosure Statement submitted herewith and the accompanying references in examination of the subject patent application.

CERTIFICATION

☐ The **undersigned** hereby certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

☐ The **undersigned** hereby certifies that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

FEES

☐ No fee is owed by the applicant(s).

☒ The **IDS Fee of \$180.00** under 37 C.F.R. § 1.17(p) is enclosed herewith.

McDonnell, Boehnen, Hulbert & Berghoff LLP
300 S. Wacker Drive, Suite 3100
Chicago, IL 60606
312-913-0001

METHOD OF PAYMENT OF FEES

☒ Charge Deposit Account No. 13-2490 in the amount of \$180.00.

Please charge any underpayment or credit any overpayment in connection with this communication to Deposit Account No. 13-2490.

US Patent Documents

1. Kearns, et al. U.S. Patent No. 5,286,646, Issued on February 15, 1994.
2. Petrossian, et al. U.S. Patent No. 4,806,484, Issued on February 21, 1989.
3. Robert D. van Reis, U.S. Patent No. 5,256,294, Issued on October 26, 1993.
4. Michael J. Gramer, U.S. Patent No. 6,001,585, Issued on December 14, 1999.

US Published Patent Applications

5. Endo, et al., U.S. Published Application No. US 2004/0014711, Published on January 22, 2004.

Other Documents

6. Falkenberg, F.W., Weichert, H. Krane, M., Bartels, I., Palme, M., Nagels, H.-O. and Feibig, H. (1995) "In vitro production of monoclonal antibodies in high concentration in a new and easy to handle modular minifermenter" Journal of Immunological Methods, 179, pp. 13-29.
7. Piret, J.M. and Cooney, C.L. (1990) "Mammalian cell and protein distributions in ultrafiltration hollow fibre bioreactors" Biotechnology and bioengineering, 36, pp. 902-910.
8. Jackson, L.R., Trudel, L.J., Fox, J.G. and Lipman, N.S. (1996) "Evaluation of hollow fibre bioreactors as an alternative to murine ascites production for small scale monoclonal antibody production" Journal of Immunological Methods, 189, pp. 217-231.

Respectfully submitted,

Date: /March 9, 2012/

/David S. Harper/
David S. Harper, Ph.D.
Registration No. 42,636

Telephone: 312-913-0001
Facsimile: 312-913-0002

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, IL 60606

McDonnell, Boehnen, Hulbert & Berghoff LLP
300 S. Wacker Drive, Suite 3100
Chicago, IL 60606
312-913-0001